Expert Highlights Importance of Molecular Testing in Patients With Lung Cancer
Fred R. Hirsch, MD, PhD, shares a message with oncologists regarding molecular testing in patients with lung cancer. He says the most important message is that molecular characterization of the patient’s tumor must be done in order to best treat the patient.
Fred R. Hirsch, MD, PhD, professor of medicine and executive director for the Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai Health System, shares a message with oncologists regarding molecular testing in patients with lung cancer. He says the most important message is that molecular characterization of the patient’s tumor must be done in order to best treat the patient.
It sounds simple, but Hirsch says not all patients with lung cancer undergo molecular testing at this time, especially in the community setting. It is not natural in that setting to get molecular testing on every patient’s tumor, but it is necessary.
Today’s lung cancer treatments are mainly based on the molecular profile of patients, especially in the setting of advanced disease. Understanding a patient’s molecular profile is essential in selecting the right treatment.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
